STERIS FY2027 Q2: revenue up 8.8%, adjusted EPS up 19.0%, outlook raised
STERIS beat on both lines and raised fiscal 2027 adjusted EPS guidance, but a chunk of that raise comes from tariff refunds rather than operations. Revenue of $1.5886 billion grew 8.8%, with 8.1% constant currency organic growth, and adjusted EPS of $2.94 rose 19.0%. Read the segments to see where the growth came from, then the cash flow line to see whether it converted.
1 · Expected vs. Actual
Free preview belowGAAP diluted EPS rose to $2.19 from $1.94, while adjusted EPS climbed 19.0% to $2.94 from $2.47. The $0.75 gap between the two is mostly $65.0 million of acquired-intangible amortization and $25.5 million of restructuring charges. Adjusted is the number management steers by, but the restructuring charge is a real cost the business incurred this quarter.
Revenue was $1.5886 billion, up 8.8% from $1.4603 billion a year ago, with constant currency organic growth of 8.1%. Life Sciences did the heavy lifting at $170.6 million, up 17.7%, while Healthcare contributed $1.1224 billion and AST $295.6 million. Acquisitions added $11.3 million, so the underlying pace is slightly below the headline.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-05
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.